BG
KNSA icon

Bellevue Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Bellevue Group’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,100
Closed -$160K – 157
2024
Q4 		$160K Buy
+8,100
New +$185K ﹤0.01% 148

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bellevue Group's KNSA Position: Q1 2025 in Review

Bellevue Group sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2025, closing a stake of 8,100 shares — an estimated $160K sold.

Bellevue Group first reported a position in KNSA in Q4 2024 and held it in 1 quarter. The position peaked at $160K in Q4 2024. 176 funds tracked by Wall St. Rank hold KNSA as of Q1 2025.

  • Bellevue Group reported no remaining Kiniksa Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Bellevue Group sold 8,100 Kiniksa Pharmaceuticals shares in Q1 2025, an estimated $160K.
  • Bellevue Group first reported a position in Kiniksa Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Bellevue Group's Kiniksa Pharmaceuticals position peaked at $160K in Q4 2024.
  • 176 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2025.

Based on Bellevue Group's 13F filing for Q1 2025, filed 14 May 2025.